Perimeter Medical Imaging AI to Showcase Innovations at 2025 Bloom Burton Healthcare Investor Conference
Perimeter Medical Imaging AI, Inc., listed on the TSXV under the ticker symbol PINK and OTCQX as PYNKF, is poised to make waves in the healthcare investment community. The company, known for its groundbreaking medical imaging technology, is set to participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place at the prestigious Metro Toronto Convention Centre on May 5, 2025, at 9:30 a.m. Eastern Time.
This participation marks a significant opportunity for the management team of Perimeter to showcase their advancements in cancer surgery technology. The firm specializes in ultra-high-resolution imaging tools, which are designed to meet critical medical needs in oncology, significantly improving surgical outcomes and patient safety. Notably, their flagship product, the Perimeter S-Series Optical Coherence Tomography (OCT) system, has received FDA clearance for general use across the United States. This system enables real-time visualization of excised tissues at a cellular level, a significant advancement in intraoperative diagnostics.
Adding to their suite of innovations is the Perimeter B-Series OCT, which includes ImgAssist AI— a next-generation artificial intelligence technology currently undergoing pivotal clinical evaluation. This system has received substantial support for its development, including a grant of up to $7.4 million awarded by the Cancer Prevention and Research Institute of Texas. Though still investigational and not available for sale in the U.S., this technology holds great promise for the future of cancer treatment and diagnostics.
Both the presentation and subsequent discussions will be available for live streaming, allowing stakeholders, investors, and interested parties to gain insights into the company’s direction and growth strategy. Viewers can easily access the live stream on Perimeter’s official website under the ‘News/Events’ section within the Investors area, ensuring transparency and fostering a connection between the company and its stakeholders.
Perimeter operates out of both Toronto and Dallas, positioning itself strategically within two key markets for medical technology. Their commitment to addressing unmet medical needs in cancer surgeries not only enhances patient care but also aligns with broader trends toward utilizing advanced imaging technologies in medicine. The company's innovative approach, reflected in their products and research initiatives, positions them as a leader in the healthcare technology sector.
For potential investors and industry watchers, this conference represents an invaluable opportunity to understand Perimeter's vision going forward. As they aim to finalize their latest product offerings and push the boundaries of what's possible in cancer surgery, all eyes will be on their presentation at Bloom Burton.
It’s important for investors to note that the U.S. regulatory landscape remains a vital aspect of Perimeter’s business strategy. The S-Series OCT is cleared for general use but has not been specifically evaluated for breast tissue or other types of cancer, highlighting the complexities and ongoing challenges that accompany medical technology advancement. Perimeter clearly states that while the benefits of their products are promising, the safety and effectiveness of these uses have not yet been finally established.
In a rapidly evolving healthcare environment, the combination of cutting-edge technology and strategic showcases such as the Bloom Burton conference signify not just corporate growth, but essential transformations in healthcare that could potentially save lives. For more details about the company and its offerings, interested parties are encouraged to visit their website, www.perimetermed.com/disclosures.
Perimeter Medical Imaging AI continues to push the frontiers of medical imaging technology, and their presence at significant investment events underscores their commitment to revolutionizing how cancer is addressed surgically in today's clinical settings.
This participation marks a significant opportunity for the management team of Perimeter to showcase their advancements in cancer surgery technology. The firm specializes in ultra-high-resolution imaging tools, which are designed to meet critical medical needs in oncology, significantly improving surgical outcomes and patient safety. Notably, their flagship product, the Perimeter S-Series Optical Coherence Tomography (OCT) system, has received FDA clearance for general use across the United States. This system enables real-time visualization of excised tissues at a cellular level, a significant advancement in intraoperative diagnostics.
Adding to their suite of innovations is the Perimeter B-Series OCT, which includes ImgAssist AI— a next-generation artificial intelligence technology currently undergoing pivotal clinical evaluation. This system has received substantial support for its development, including a grant of up to $7.4 million awarded by the Cancer Prevention and Research Institute of Texas. Though still investigational and not available for sale in the U.S., this technology holds great promise for the future of cancer treatment and diagnostics.
Both the presentation and subsequent discussions will be available for live streaming, allowing stakeholders, investors, and interested parties to gain insights into the company’s direction and growth strategy. Viewers can easily access the live stream on Perimeter’s official website under the ‘News/Events’ section within the Investors area, ensuring transparency and fostering a connection between the company and its stakeholders.
Perimeter operates out of both Toronto and Dallas, positioning itself strategically within two key markets for medical technology. Their commitment to addressing unmet medical needs in cancer surgeries not only enhances patient care but also aligns with broader trends toward utilizing advanced imaging technologies in medicine. The company's innovative approach, reflected in their products and research initiatives, positions them as a leader in the healthcare technology sector.
For potential investors and industry watchers, this conference represents an invaluable opportunity to understand Perimeter's vision going forward. As they aim to finalize their latest product offerings and push the boundaries of what's possible in cancer surgery, all eyes will be on their presentation at Bloom Burton.
It’s important for investors to note that the U.S. regulatory landscape remains a vital aspect of Perimeter’s business strategy. The S-Series OCT is cleared for general use but has not been specifically evaluated for breast tissue or other types of cancer, highlighting the complexities and ongoing challenges that accompany medical technology advancement. Perimeter clearly states that while the benefits of their products are promising, the safety and effectiveness of these uses have not yet been finally established.
In a rapidly evolving healthcare environment, the combination of cutting-edge technology and strategic showcases such as the Bloom Burton conference signify not just corporate growth, but essential transformations in healthcare that could potentially save lives. For more details about the company and its offerings, interested parties are encouraged to visit their website, www.perimetermed.com/disclosures.
Perimeter Medical Imaging AI continues to push the frontiers of medical imaging technology, and their presence at significant investment events underscores their commitment to revolutionizing how cancer is addressed surgically in today's clinical settings.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.